Our Bureau
Piscataway, NJ
Kashiv BioSciences, LLC, a global vertically integrated biopharmaceutical company, recently announced the appointment of Dr. Sandeep Nilkanth Athalye as Global Chief Executive Officer. Dr. Athalye, a seasoned leader with over two decades of experience in strategic and operational roles within the global pharmaceutical industry, will oversee company operations and drive strategic growth across key markets, including the United States, Europe, and Asia.
Dr. Athalye, Global CEO, stated, “Kashiv is an ambitious biosimilars company founded with a vision to bring affordable and accessible biosimilars globally. Kashiv has a clear objective to be among the top biosimilars players with a differentiated pipeline and state-of-the-art manufacturing and R&D facilities in the U.S. and India. I am very excited for the opportunity to use technology and innovation to drive Kashiv to become one of the leading developers of medicines in the biologics space.”
Dr. Athalye is recognized for his focus on innovative, patient-centric strategies and his commitment to sustainable growth. Dr. Athalye’s previous leadership roles span Biocon Biologics, Boehringer Ingelheim, Novartis, and Schering-Plough Research Institute.
Chirag and Chintu Patel, Co-Founders and Board Members of Kashiv BioSciences, stated, “We are delighted to welcome Dr. Athalye to Kashiv. His appointment comes at a pivotal time as we accelerate our growth in the rapidly expanding biosimilars sector. We are confident that Dr. Athalye’s industry expertise and leadership will be instrumental in achieving Kashiv’s ambitious global vision.”
Dr. Athalye holds a MBBS in Medicine from Bharati Vidyapeeth, a MS in Clinical Pharmacology from The University of Toledo, and MBA in BioPharma Innovation from Rutgers University.
